Whitehawk Therapeutics, Inc. 8-K

What Happened
Whitehawk Therapeutics, Inc. (WHWK) filed an Form 8‑K on May 21, 2026 announcing an option agreement with Hangzhou DAC Biotechnology that expands Whitehawk’s antibody‑drug conjugate (ADC) pipeline by providing access to the CPT113 linker‑payload for use in up to five additional ADC programs. The filing also notes that Hangzhou DAC presented data at the American Society of Clinical Oncology (ASCO) Annual Meeting for DXC006, an ADC that utilizes the CPT113 linker‑payload. A press release dated May 21, 2026 is attached as Exhibit 99.1.

Key Details

• Option agreement grants Whitehawk access to CPT113 linker‑payload for up to five additional ADC programs.
• Announcement made via Form 8‑K filed May 21, 2026; press release attached as Exhibit 99.1.
• Hangzhou DAC presented data at the ASCO Annual Meeting for DXC006, which uses CPT113.
• The filing does not disclose financial terms, timelines, or exclusivity details.

Why It Matters
This filing signals Whitehawk is expanding its ADC technology options by securing rights to a specific linker‑payload (CPT113), which is a core component in ADC design. Access to CPT113 for multiple programs could enable development of additional drug candidates without Whitehawk having to independently develop that payload chemistry. The ASCO presentation for DXC006 highlights that CPT113 is already being used in at least one clinical program, providing publicly available data points investors can review. No financial or timing specifics were provided in the 8‑K.